A 35-year-old man from Bangalore with Graves' disease has been on methimazole 10 mg daily for 2 months. He now presents with fever, sore throat, and severe mouth ulcers. His total WBC count is 1,200/µL (normal 4,500–11,000/µL) with neutrophils 15%. He denies recent infections or other drug use. What is the most appropriate immediate management?

Explanation

## Management of Antithyroid Drug-Induced Agranulocytosis **Key Point:** Agranulocytosis is a rare but life-threatening adverse effect of antithyroid drugs (PTU and methimazole). It requires immediate discontinuation of the offending agent, switch to an alternative, and aggressive supportive care including antibiotics and monitoring. ### Clinical Presentation of Agranulocytosis The triad in this patient is classic: 1. **Fever** — due to severe infection from neutropenia 2. **Sore throat and mouth ulcers** — mucosal breakdown from lack of neutrophils 3. **Severe leukopenia** (WBC 1,200/µL, neutrophils 15%) — absolute neutrophil count (ANC) <500/µL is diagnostic ### Pathophysiology Antithyroid drugs (especially methimazole and PTU) can cause agranulocytosis through: - **Dose-dependent mechanism** (rare, reversible with dose reduction) - **Idiosyncratic immune-mediated mechanism** (more common, unpredictable, irreversible) — this patient likely has the idiosyncratic form given the acute presentation **High-Yield:** Agranulocytosis occurs in 0.1–0.3% of patients on antithyroid drugs, typically within the first 3 months of therapy. This patient is at day 60, which is within the high-risk window. ### Immediate Management Algorithm ```mermaid flowchart TD A[Antithyroid drug + fever + sore throat + WBC <1500]:::outcome --> B{Suspect agranulocytosis?}:::decision B -->|Yes| C[STOP antithyroid drug immediately]:::urgent C --> D[Switch to alternative antithyroid]:::action D --> E{Which alternative?}:::decision E -->|From methimazole| F[Switch to PTU]:::action E -->|From PTU| G[Switch to methimazole]:::action F --> H[Start broad-spectrum antibiotics]:::action G --> H H --> I[Supportive care: IV fluids, transfusions PRN]:::action I --> J[Monitor WBC daily until recovery]:::action J --> K[Consider G-CSF if severe/prolonged]:::action ``` ### Why Each Option Is Correct or Wrong | Management Step | Rationale | |-----------------|----------| | **Discontinue methimazole** | Mandatory — continuing the offending drug risks fatal sepsis | | **Switch to PTU** | PTU is the alternative when methimazole causes agranulocytosis; cross-reactivity is rare but possible, so close monitoring is essential | | **Broad-spectrum antibiotics** | Covers gram-positive and gram-negative organisms; empiric therapy is critical because the patient is severely immunocompromised | | **Supportive care** | IV fluids, blood/platelet transfusions as needed, isolation from infectious sources | | **Daily WBC monitoring** | Tracks recovery; agranulocytosis from idiosyncratic reactions may take weeks to resolve | | **G-CSF (granulocyte colony-stimulating factor)** | Reserved for severe, prolonged cases or if signs of sepsis worsen; accelerates neutrophil recovery | **Clinical Pearl:** Do NOT attempt dose reduction or continue the drug. Idiosyncratic agranulocytosis does not improve with dose reduction and is a medical emergency. The mortality rate is ~5–10% if not managed promptly. ### Why Continuing Methimazole Is Wrong Option A (continue methimazole + G-CSF) is dangerous because: - The idiosyncratic form of agranulocytosis is **not dose-dependent** and will not resolve by reducing the dose. - Continuing the offending drug risks overwhelming sepsis and death. - G-CSF alone without stopping the drug is insufficient. ### Why Iodine Solution Alone Is Inadequate Option D (discontinue methimazole + iodine) has merit in stopping the drug but is incomplete because: - Iodine solution is short-acting and will not provide sustained antithyroid control. - It does not address the life-threatening agranulocytosis, which requires antibiotics and supportive care. - Iodine can cause escape phenomenon and is not suitable for long-term management. ### Why Dose Reduction Is Not Appropriate Option C (reduce dose + folinic acid) is incorrect because: - Folinic acid (leucovorin) is used in methotrexate toxicity, not antithyroid drug agranulocytosis. - Dose reduction does not help idiosyncratic agranulocytosis. - The patient needs immediate drug discontinuation and alternative therapy. **Mnemonic for Antithyroid Adverse Effects:** - **PTU**: Hepatotoxicity (rare but serious), agranulocytosis, rash, arthralgia - **Methimazole**: Agranulocytosis, rash, arthralgia, methimazole embryopathy (in pregnancy) - **Both**: Agranulocytosis (0.1–0.3%), vasculitis, lupus-like syndrome [cite:KD Tripathi 8e Ch 42; Harrison 21e Ch 397]